Skip to main
BIIB

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 24%
Buy 24%
Hold 48%
Sell 5%
Strong Sell 0%

Bulls say

Biogen's stock has experienced a significant rally, with shares rising approximately 35% since the beginning of the third quarter of 2025, in contrast to a 40% increase in the broader biopharmaceutical index. The company is strategically positioned with key new product launches such as Leqembi, Skyclarys, and Zurzuvae, which have outperformed expectations and may drive near-term earnings growth. Additionally, Biogen’s expanding neuroscience portfolio and strong cash flow support continued investment in high-risk research and development, further enhancing its market position and potential for revenue growth.

Bears say

Biogen is projected to experience a significant decline in revenue, with estimates dropping from $9.8 billion in 2025 to $5.1 billion by 2040, falling below consensus expectations and reflecting a largely flat revenue compound annual growth rate (CAGR) from 2026 to 2030. The company's major dependency on its multiple sclerosis (MS) franchise, which is facing intensifying competition and the impending launch of biosimilars, particularly threatens its revenue stream, as evidenced by guidance indicating a 5-8% decrease in global MS revenues in the latter half of 2025. Additionally, declining royalties from key collaborations, particularly with Roche, along with anticipated challenges for its newer products and the overall EBITDA CAGR turning negative at (4%) from 2026 to 2030, further contribute to the negative outlook on Biogen's financial trajectory.

Biogen (BIIB) has been analyzed by 21 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 24% recommend Buy, 48% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 21 analysts, Biogen (BIIB) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $184.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $184.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.